Introduction
The level of clinical trials in which compression devices are used to treated venous disease is frequently poor, 1,2 with lack of standardisation in methodology and measurement. It is desirable to develop a set of guidelines for clinical trials with compression devices In order to ensure a consistent approach in design and reporting of data. Currently no guidelines have been published either on a national or an international level.
Methods
These guidelines were prepared by a group of distinguished experts each of whom has published scientific work in the field of venous disease (Table 1) . This group refers to its members as the 'International Compression Club (ICC). Published papers relevant to these guidelines are identified from searching the medical literature databases Medline and Embase, and on the UIP-consensus on evidence-based compression-therapy. 2 The meeting of the ICC at which the first draft of the guidelines was discussed took place in Cologne the 17th September 2005. The results of this discussion were included in a further draft which was then sent by e-mail to the experts of the group for further comment. Further versions of the document were circulated to the group until agreement of all members was obtained. The resulting text appears below.
General, legal and formal aspects
Studies must be planned, conducted and evaluated according to current directives and guidelines, examples of which are given at the end of this chapter. 3, 4, 5, 6, 7 It is a legal requirement to follow local or national laws concerning the conduct of clinical trials, and this takes precedence over international guidelines. As differing directives and guidelines may apply in different countries, investigators must ensure that the relevant national instructions are taken into account. It is recognised that directives and guidelines change, so it is important to ensure that the most recent version of these documents is identified and used.
In order to conduct a clinical trial of the efficacy and safety of a treatment or method with uncertified medical devices, approved medical devices or handling instructions used in off-label indications or with additional unusual burdens for the patient, a study protocol with all additional necessary documents or approvals must be prepared. The items that must be clearly described are listed in Table 2 .
Registration with or approval by the relevant national authorities may be necessary depending on the national or local law.
The results of the study should be summarised in a clinical, biometric report containing critical comments on the study concept, the study methodology and interpretation of the results, and take into account the clinical and scientific knowledge available. The report should draw conclusions for the medical profession, the medical device manufacturer and, where appropriate, the health authorities and any other bodies. This comprehensive report constitutes part of the clinical trial and is necessary regardless of whether or not the study is to be published. The conduct of clinical studies with certified medical devices used in their certified indications or 'instructions for use' are governed by minor regulatory requirements e also dependent on the current national or local law.
Examples of directives and guideline and internet URLs: The CEAP classification system for chronic venous disorders takes into account clinical, etiological, anatomical and pathophysiological factors. Its informative value has been validated. We therefore recommend that patients with chronic venous diseases be classified according to their CEAP classification for future studies. In addition, the CEAP classification system offers a limited assessment of changes in the clinical scoring system. 8 The use of the Basic CEAP classification is mandatory. 8 For studies that require greater patient differentiation the Scientific CEAP classification is recommended. 8 However, since CEAP is mainly a descriptive In studies on patients with acute venous diseases the classification must include exact localisation, extent and duration of the changes.
Requirements

Principal requirements
The form of compression therapy including the comparator(s) used in the clinical study must be characterized.
Medical compression garments
The following data should be given: type and size of the compression garment (calf, thigh) the kind of material, flat or round knitted the pressure range at ankle level (mm Hg, measuring method), pressure according to manufacturer's labelling the pressure gradient Ready to wear or made to measure
The following data should be encouraged:
Slope/stiffness of the material In vivo pressure values
The compression garment used must be marked (e.g. with a code) to ensure that the same garment is used during the study.
Compression bandages
The following data should be given:
Material, number and type of components Size (length with and without stretch, width) of the bandage (if measured with stretch the percentage of stretch needs to be given) Length of the bandage system (calf, thigh) Technique of application (spiral, figure-of eight, overlap)
Stiffness of the final bandage (system) In vivo pressure values
The size of the ankle should be recorded in all trials. This ensures that the correct choice of bandages is made for all patients. While most ankle sizes range from 20 to 25 cm there is a proportion with very small and large limbs.
Pumps and other mechanical devices
Number and type of pressure chambers Pressure distribution Pressure applied Pumping cycles B Inflation and deflation characteristics B Duration B Number
In comparative trials the above-mentioned characteristics should be declared for all compression devices tested or used.
Further requirements
The following points should be considered depending on the details of the study:
Material
The declaration of fibre content, extensibility in longitudinal and transverse direction and of stiffness (hysteresis-curve) are desirable (see above).
The influence exerted by the compression product on resting and working pressures depends upon the extensibility of compression material. The elastic properties of a compression bandage or system are affected by the number of layers in the system, whereby the greater the number of layers, the greater the effect. Details on the number and nature of layers must be provided.
In future studies the characteristics of the material provided by the manufacturer should be declared including the in vivo data on pressure and on stiffness of the final compression system on the individual leg. 10 It has to be declared whether bandages have been washed or not.
Person applying the compression device Compression trials are very user dependant. Every attempt should be made to limit the number of people applying the bandages within a trial as considerable variation occurs between experienced bandagers. All personnel involved in applying bandages (patient, relatives, medical staff) should have a formal standardized training which includes pressure measurements of their technique.
Duration of compression and concordance
The time of compression per day and the total wear time must be noted and patients' concordance must be documented.
Concordance where possible should be recorded by the patient and assessed by a blinded assessor to avoid the temptation of labelling ''deviant'' patients.
Previous compression therapy
What kind and for how long.
Durability and costs
Durability, reusability and costs of the material should be described where applicable.
Cost-effectiveness
Cost-effectiveness evaluation is desirable in clinical studies depending on the size and nature of the study. There is a wide range of possible analyses including cost minimisation, cost reduction, cost-benefit relation etc. Clinical trials should aim to measure cost effectiveness which allows both clinical and cost outcomes to be considered together.
Physical activity
Physical activity and walking ability of the patient (ADL ¼ Activities of daily living) should be described. The daily walking distance or activity may be measured using a pedometer.
Validated tools for measuring activities of daily living are recommended. Independent risk factors for ulcer healing have been identified, like general mobility status (chair/bedbound, walking outside unaided, walking inside aided and walking freely) and ankle function (full movement, reduced ankle function, fixed ankle joint).
Quality of life
Patient reported outcome (PRO) and Quality of life (QoL). Validated, disease-specific and generic Quality of life questionnaires should be used. 11, 12, 13, 14 Pressure The pressure exerted on the distal lower leg should be given in mmHg and the method of pressure determination must be quoted. Report of in vivo pressure using a pressure sensor specific to a manufacturer is not recommended. Compression classes vary considerably between different countries (Table 3) .
In order to find a clear and internationally acceptable language we propose to replace compression classes by pressure ranges at the ankle region, declaring the in vitro-method of measurement: e. g. 10e20 mmHg, 20e30 mmHg, 30e40 mmHg, >40 mmHg.
The pressure values given by the manufacturers of medical compression hosiery are measured by different methods (e.g. ITF, HOSY, HATRA). For future trials the additional measurement of in vivo pressure is encouraged.
Several instruments are available for measuring the in vivo -pressure exerted by compression garments on patients' limbs. 15, 16 Recommendations as to how and where the pressure should be measured have been proposed by the ICC. 17 Several important points have to be considered (Table 4) .
It is recommended that any pressure sensor that is considered for use should satisfy, or come close to, the following key specifications: 17 The sensor should be thin and flexible. Based on theoretical model calculations that are mainly valid for flat areas a maximal sensor thickness of 0.5 mm is suggested. The sensitive area of the sensor should be adjustable and optimized for different applications (leg, hand, toe) and different measuring regimes: e. g. small areas for mapping of a circumferential pressure pattern, large sensor areas (over 5 cm 2 ) for measuring the integral pressure of a larger area taking advantage of the fact that the local pressure distribution will be averaged over changing curvatures of the leg segment. The sensor should be able to be left in contact with the leg for extended periods of time without skin irritation and should keep its accuracy. 
Methods of Measurement
Parameters and methods
Many parameters and methods are applicable for measuring a variety of compression effects (Table 5) . This does not mean that all methods should be used together in future trials. Methods should be selected according to the specific objective of the study. For any vein diameter or any haemodynamic parameter the position must be specified (supine position, sitting position, standing position on both feet or on contralateral foot).
Definition of the level of arterial disease, an ABPI of 0.8 or above can be accepted.
In ulcer trials risk factors that affect healing rates should be documented, e. g. Body Mass Index (BMI). At least ulcer size and ulcer duration, which are the two most important predictive factors.
Examples for outcome parameters in future compression studies
The outcome parameters used and presented should be selected according to the different stages of chronic venous diseases included in trials (Table 6 ). All methods used for clinical studies must be validated. In all CEAP stages, quality of life, standardized evaluation of patients' satisfaction, venous severity scoring, changes in CEAP-classification, and VAS for subjective complaints should be used. In all stages compliance with compression must be documented. For standardized photodocumentation, assessment by blinded observers is preferred. Long term assessment is preferred in all stages although it is recognised that this may not always be feasible. (Table 6 ) Recanalisation of a vein duplex, measurement of outflow fraction by strain gauge or air plethysmography (APG), quantitative assessment of refluxes by measuring venous filling index (ml(sec) using APG Lipodermatosclerotic skin changes skin thickness with high frequency ultrasound (e.g. 20 MHz), CT, NMR, by the durometer, tissue compliance monitor 18, 19 Ulcer healing incidence of complete healing, area-planimetry, area in cm 2 Â p/4 (ellipse), Gillman method healing rate per unit time with correction for ulcer size (A b ÀA a )/(P a þ P b )/2) (bÀa) [A: area of ulcer, P: perimeter, a: start and b: end of the observation], time to complete healing, life table analysis should include all patients, including those lost to follow up and treatment failures 20 Clinical parameters symptoms on analogue scale including pain, CEAP, classification and VSS, QoL
Establishing a reliable diagnosis of chronic venous disorders and acute venous diseases
It must be reliably determined that the clinical findings in each study subject are the result of a disturbance of venous haemodynamics. A clinical examination is not sufficient to do this. The clinical picture as well as the pathological changes need to be specified using imaging and functional methods:
Imaging methods include duplex sonography, phlebography or MRI which can be used to localise a venous disorder in the sub-and extra-fascial venous system.
Functional methods include duplex and Doppler sonography to demonstrate reflux in the superficial and/ or deep veins. Phlebodynamometry (measurement of intravenous pressure) is currently to be regarded as the reference procedure to record venous pumping action. Alternative methods include various forms of plethysmography such as the strain gauge method, foot volumetry and photoplethysmographic methods.
Acute venous diseases must be documented and classified by imaging methods (e.g. duplex, phlebography).
Study Criteria
Inclusion criteria
B Signed informed consent declaration/data protection declaration B Exact diagnosis based on the CEAP classification
Precautions
The following points which may be exclusion criteria should be carefully considered B Diseases/symptoms that imitate the symptomatology of venous disease (e.g. lymphoedema, lipoedema) B Heart failure B Severe renal and hepatic failure B Competing/interfering, concomitant systemic and local drug treatments (no newly started medication with a vascular or cardiovascular effect should be taken/administered during the treatment) B Known allergies to the compression material Continued treatment of other diseases is allowable depending on the test parameters chosen, and with the proviso that the treatment will not interfere with the trial outcome. Any concomitant medication must be recorded.
Withdrawal criteria
B Deterioration in the clinical picture of venous disorders (e.g. progression to a higher stage of CVI) if not indicated in the designed study population B Lack of concordance by the patient B Withdrawal of patients consent (reasons for withdrawal of patient consent should be documented) B Change in measures and events that affect the target criteria Example: Initiation, change or discontinuation of hormone therapy, diuretic treatment B Intercurrent infections of the lower extremity
Perspective
The present recommendations for testing the therapeutic efficacy of compression treatments in patients with venous disorders are designed to help to determine the significance of the various treatment modalities more accurately and consistently by means of qualified clinical studies.
